Phase II Study of 2-weekly RAILIRI Versus FOLFIRI as Second-line Treatment in Advanced Colorectal Cancer Patients
This study is designed to compare the efficacy and safety of two-weekly RAILIRI regimen with FOLFIRI regimen in the treatment of advanced colorectal cancer patients in the second-line setting.
Colorectal Carcinoma
DRUG: Raltitrexed|DRUG: Irinotecan|DRUG: 5-fluorouracil|DRUG: Leucovorin
progression free survival, 2 months
overall survival, 6 months|overall response rate, 2 months|disease control rate, 2 months|Number of Participants with Adverse Events, 2 months|quality of life questionnaire, 2 months
This study is designed to compare the efficacy and safety of two-weekly RAILIRI regimen with FOLFIRI regimen in the treatment of advanced colorectal cancer patients in the second-line setting.